× Key messages Background Findings Perspectives Expert commentary
Go back | list
format_size dark_mode
icon-previous icon-next

Background

What do we already know about this topic?

  • Automated insulin delivery consists of a pump, connected continuous glucose monitoring, and automated dosing algorithm.
  • No prior study has a commercially approved automated insulin delivery arm.

How was this study conducted?

  • This trial (NCT03040414) compared the Advanced Hybrid Closed-Loop (AHCL) system to 670G.
  • Patients were randomized to one of the devices for 12 weeks and then crossed over to the other device for another 12 weeks.
  • 111 people (adolescents and young adults, age 14 to 29) with type 1 diabetes of seven international diabetes centers completed the trial; mean HbA1c was 7.9% at baseline.